[go: up one dir, main page]

EE200200248A - Adenosiini retseptori antagonistid ja nende valmistamise ja kasutamise meetodid - Google Patents

Adenosiini retseptori antagonistid ja nende valmistamise ja kasutamise meetodid

Info

Publication number
EE200200248A
EE200200248A EEP200200248A EEP200200248A EE200200248A EE 200200248 A EE200200248 A EE 200200248A EE P200200248 A EEP200200248 A EE P200200248A EE P200200248 A EEP200200248 A EE P200200248A EE 200200248 A EE200200248 A EE 200200248A
Authority
EE
Estonia
Prior art keywords
preparation
methods
receptor antagonists
adenosine receptor
adenosine
Prior art date
Application number
EEP200200248A
Other languages
English (en)
Estonian (et)
Inventor
Lee Ensinger Carol
E. Dowling James
Kumaravel Gnanasambandam
C. Petter Russell
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200200248A publication Critical patent/EE200200248A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EEP200200248A 1999-11-12 2000-11-13 Adenosiini retseptori antagonistid ja nende valmistamise ja kasutamise meetodid EE200200248A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16528399P 1999-11-12 1999-11-12
PCT/US2000/031100 WO2001034604A2 (en) 1999-11-12 2000-11-13 Adenosine receptor antagonists and methods of making and using the same

Publications (1)

Publication Number Publication Date
EE200200248A true EE200200248A (et) 2003-06-16

Family

ID=22598257

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200248A EE200200248A (et) 1999-11-12 2000-11-13 Adenosiini retseptori antagonistid ja nende valmistamise ja kasutamise meetodid

Country Status (33)

Country Link
US (4) US6605600B1 (xx)
EP (2) EP1775297A3 (xx)
JP (1) JP2003513976A (xx)
KR (1) KR100845488B1 (xx)
CN (1) CN1187354C (xx)
AT (1) ATE353328T1 (xx)
AU (1) AU784528B2 (xx)
BG (1) BG106693A (xx)
BR (1) BR0015540A (xx)
CA (1) CA2390590C (xx)
CY (1) CY1106560T1 (xx)
CZ (1) CZ20021615A3 (xx)
DE (1) DE60033310T2 (xx)
DK (1) DK1230241T3 (xx)
EA (1) EA010260B1 (xx)
EE (1) EE200200248A (xx)
ES (1) ES2281367T3 (xx)
GE (1) GEP20043267B (xx)
HK (1) HK1049153B (xx)
HU (1) HUP0203371A3 (xx)
IL (1) IL149486A0 (xx)
IS (1) IS6380A (xx)
MX (1) MXPA02004795A (xx)
NO (1) NO20022237L (xx)
NZ (2) NZ519427A (xx)
PL (1) PL198156B1 (xx)
PT (1) PT1230241E (xx)
SK (1) SK6622002A3 (xx)
TR (1) TR200301062T2 (xx)
UA (1) UA77937C2 (xx)
WO (1) WO2001034604A2 (xx)
YU (1) YU33702A (xx)
ZA (1) ZA200203702B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
IL149486A0 (en) * 1999-11-12 2002-11-10 Biogen Inc Purine derivatives and pharmaceutical compositions containing the same
EP1230243B1 (en) * 1999-11-12 2009-03-04 Biogen Idec MA Inc. Poycyloalkylpurines as adenosine receptor antagonists
CN1671716A (zh) * 2002-06-12 2005-09-21 拜奥根Idec马萨诸塞公司 用腺苷受体拮抗剂治疗缺血再灌注损伤的方法
AU2003261206A1 (en) * 2002-07-19 2004-02-09 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
CA2522323C (en) * 2003-04-14 2009-09-15 Pfizer Products Inc. 3-azabicyclo[3.2.1]octane derivatives as opioid receptor ligands
RU2367442C2 (ru) * 2003-04-25 2009-09-20 Новокардия, Инк. Способ нормализации мочеиспускания при нарушении функции почек
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
WO2007103776A2 (en) * 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
AU2007235372A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine A1 receptor antagonists and anticonvulsants
MX2008014672A (es) 2006-05-19 2009-03-09 Abbott Lab Derivados de alcano azabiciclico sustituidos con bicicloheterociclo fusionado activos en el sistema nervioso central.
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
US20090228097A1 (en) * 2008-03-07 2009-09-10 Abbott Cardiovascular Systems Inc. A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device
CN114790164B (zh) 2021-08-13 2022-12-27 苏州璞正医药有限公司 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155664A (en) * 1959-11-13 1964-11-03 Endo Lab Derivatives of theophylline
DE8817122U1 (de) 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
JPH06102662B2 (ja) 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
ES2152207T3 (es) 1989-10-20 2001-02-01 Kyowa Hakko Kogyo Kk Derivados condensados de la purina.
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
DE69229257D1 (de) 1991-11-08 1999-07-01 Kyowa Hakko Kogyo Kk Xanthinderivate zur Behandlung der Demenz
US5336769A (en) 1992-02-17 1994-08-09 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5342841A (en) 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
TW252044B (xx) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
WO1994016702A1 (fr) 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'elimination irreguliere des matieres fecales
JP3729874B2 (ja) * 1993-04-07 2005-12-21 協和醗酵工業株式会社 キサンチン誘導体
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
AU7675598A (en) 1997-06-16 1999-01-04 Kyowa Hakko Kogyo Co. Ltd. Hepatic edema remedy
AU7675498A (en) 1997-06-16 1999-01-04 Kyowa Hakko Kogyo Co. Ltd. Preventive and remedy for drug-induced nephropathy
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
US6489331B1 (en) 1998-07-02 2002-12-03 Kyowa Hakko Kogyo Co., Ltd. Remedies for diabetes
EP1230243B1 (en) * 1999-11-12 2009-03-04 Biogen Idec MA Inc. Poycyloalkylpurines as adenosine receptor antagonists
IL149486A0 (en) * 1999-11-12 2002-11-10 Biogen Inc Purine derivatives and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
AU784528B2 (en) 2006-04-27
EP1775297A2 (en) 2007-04-18
DE60033310T2 (de) 2007-11-22
CY1106560T1 (el) 2012-01-25
US20030225038A1 (en) 2003-12-04
YU33702A (sh) 2005-03-15
HUP0203371A3 (en) 2005-02-28
KR20020049043A (ko) 2002-06-24
BR0015540A (pt) 2002-07-23
NZ519427A (en) 2003-08-29
HK1049153A1 (en) 2003-05-02
CN1187354C (zh) 2005-02-02
US6605600B1 (en) 2003-08-12
EA010260B1 (ru) 2008-06-30
EP1230241A2 (en) 2002-08-14
ATE353328T1 (de) 2007-02-15
CN1399636A (zh) 2003-02-26
UA77937C2 (en) 2007-02-15
IS6380A (is) 2002-05-10
US20080004293A1 (en) 2008-01-03
IL149486A0 (en) 2002-11-10
JP2003513976A (ja) 2003-04-15
NO20022237D0 (no) 2002-05-10
TR200301062T2 (tr) 2003-09-22
AU2042101A (en) 2001-06-06
US20050222179A1 (en) 2005-10-06
CA2390590A1 (en) 2001-05-17
PL198156B1 (pl) 2008-05-30
WO2001034604A3 (en) 2002-01-10
NO20022237L (no) 2002-07-12
HK1049153B (en) 2007-09-28
HUP0203371A2 (hu) 2003-02-28
DE60033310D1 (de) 2007-03-22
KR100845488B1 (ko) 2008-07-10
ZA200203702B (en) 2003-10-29
NZ527918A (en) 2005-05-27
PT1230241E (pt) 2007-05-31
DK1230241T3 (da) 2007-06-04
WO2001034604A2 (en) 2001-05-17
PL356044A1 (en) 2004-06-14
MXPA02004795A (es) 2005-07-01
EP1775297A3 (en) 2008-12-03
CA2390590C (en) 2010-03-16
EP1230241B1 (en) 2007-02-07
EA200200562A1 (ru) 2002-10-31
GEP20043267B (en) 2004-06-25
CZ20021615A3 (cs) 2002-08-14
BG106693A (bg) 2003-01-31
ES2281367T3 (es) 2007-10-01
SK6622002A3 (en) 2003-02-04

Similar Documents

Publication Publication Date Title
CY1110512T1 (el) Πολυκυκλοαλκυλοπουρινες ως ανταγωνιστες υποδοχεων αδενοσινης
CY1106560T1 (el) Ανταγωνιστες υποδοχεα αδενοσινης και μεθοδοι κατασκευης και χρησης αυτων
WO1997020823A3 (en) 2-amino quinazoline derivatives as npy receptor antagonists
DK1196397T3 (da) Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
WO2003048164A3 (en) Adenosine a2a receptor antagonists
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
CA2094702A1 (en) Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
CA2275686A1 (en) Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
ATE321044T1 (de) C-6 ringsubstituierte pyrido(1,2- a)benzimidazolderivate zur behandlung von störungen des zentralen nervensystems
NO20053612L (no) 1,2,4-triaminobenzenderivater nyttige for behandling av forstyrrelser i sentralnervesystemet
SI1200402T1 (sl) Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj

Legal Events

Date Code Title Description
HC1A Change of owner name